Cutler Group’s Prelude Therapeutics PRLD Stock Holding History

Cutler Group’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-600	Closed	-$1K	–	4505
2022 Q4	$1K	Buy	+600	New	+$3.85K	﹤0.01%	4120

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's PRLD Position: Q4 2023 in Review

Cutler Group sold out of Prelude Therapeutics (PRLD) in Q4 2023, closing a stake of 130 shares.

Cutler Group first reported a position in PRLD in Q1 2022 and held it in 6 quarters. The position peaked at $12K in Q1 2023. 56 funds tracked by Wall St. Rank hold PRLD as of Q4 2023.

Cutler Group reported no remaining Prelude Therapeutics position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 130 Prelude Therapeutics shares in Q4 2023.
Cutler Group first reported a position in Prelude Therapeutics in Q1 2022 and held it in 6 quarters.
Cutler Group's Prelude Therapeutics position peaked at $12K in Q1 2023.
56 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.